Oral evidence transcript
| Published on: | Monday 24 October 2016 |
|---|---|
| Date: | Wednesday 19 October 2016 |
| Meeting on: | Wednesday 19 October 2016 |
| Part of event segment: | Untitled |
| Document ID: | 155257 |
Committees
Work packages
- Tuesday 5 April 2016 - Wednesday 3 May 2017
Witnesses
-
Dr Ian Hudson, Chief Executive, Medicines and Healthcare Products Regulatory Agency, Professor Paul Whiting, Member, Medical Research Council Regenerative Medicine Research Committee, Dr Sven Kili, Head of Gene Therapy Development, GlaxoSmithKline, and Michael Hunt, Chief Financial Officer, ReNeuron Group; Ian Trenholm, Chief Executive, NHS Blood and Transplant, Ian McCubbin, Medicines Manufacturing Industry Partnership and co-chair of the Advanced Therapy Manufacturing Taskforce, Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult, and Dr Ruth McKernan, Chief Executive, Innovate UK